OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar

OPKO Health, Inc. 0.00%

OPKO Health, Inc.

OPK

1.23

0.00%

It's not a stretch to say that OPKO Health, Inc.'s (NASDAQ:OPK) price-to-sales (or "P/S") ratio of 1.3x right now seems quite "middle-of-the-road" for companies in the Healthcare industry in the United States, where the median P/S ratio is around 1.2x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.

View our latest analysis for OPKO Health

ps-multiple-vs-industry
NasdaqGS:OPK Price to Sales Ratio vs Industry December 30th 2023

How OPKO Health Has Been Performing

OPKO Health could be doing better as its revenue has been going backwards lately while most other companies have been seeing positive revenue growth. It might be that many expect the dour revenue performance to strengthen positively, which has kept the P/S from falling. You'd really hope so, otherwise you're paying a relatively elevated price for a company with this sort of growth profile.

If you'd like to see what analysts are forecasting going forward, you should check out our free report on OPKO Health.

Do Revenue Forecasts Match The P/S Ratio?

In order to justify its P/S ratio, OPKO Health would need to produce growth that's similar to the industry.

Retrospectively, the last year delivered a frustrating 29% decrease to the company's top line. As a result, revenue from three years ago have also fallen 26% overall. So unfortunately, we have to acknowledge that the company has not done a great job of growing revenue over that time.

Turning to the outlook, the next three years should generate growth of 8.3% per annum as estimated by the six analysts watching the company. Meanwhile, the rest of the industry is forecast to expand by 8.8% per year, which is not materially different.

With this information, we can see why OPKO Health is trading at a fairly similar P/S to the industry. Apparently shareholders are comfortable to simply hold on while the company is keeping a low profile.

The Key Takeaway

It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.

Our look at OPKO Health's revenue growth estimates show that its P/S is about what we expect, as both metrics follow closely with the industry averages. Right now shareholders are comfortable with the P/S as they are quite confident future revenue won't throw up any surprises. All things considered, if the P/S and revenue estimates contain no major shocks, then it's hard to see the share price moving strongly in either direction in the near future.

A lot of potential risks can sit within a company's balance sheet. You can assess many of the main risks through our free balance sheet analysis for OPKO Health with six simple checks.

Of course, profitable companies with a history of great earnings growth are generally safer bets. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via